Search clinical trials for: oxymorphone hydrochloride

Total 7341 results

Endo Pharmaceuticals

Suspended

Safety, Tolerability, Effectiveness, and Pharmacokinetic Data in Opioid-experienced Children

Chronic Pain | Postsurgical Pain

United States
Sandoz

Completed

Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fed Conditions

Pain
Icahn School of Medicine at Mount Sinai
Endo Pharmaceuticals

Completed

A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)

Pain

United States
Endo Pharmaceuticals

Completed

Post-operative Efficacy and Safety Study

Post-operative Pain
Endo Pharmaceuticals

Completed

Oxymorphone Extended Release (ER) in Opioid-Naive Patients With Chronic Pain

Pain | Chronic Disease
Member Companies of the Opioid PMR Consortium

Terminated

Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain

Opioid-Related Disorders | Drug Abuse | Opiate Addiction | Narcotic Abuse

United States
Endo Pharmaceuticals

Withdrawn

Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects

Chronic Pain
Endo Pharmaceuticals

Completed

Open Label Assessment of Long-Term Safety and Utility

Pain
Sandoz

Completed

Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted Conditions

Pain
Icahn School of Medicine at Mount Sinai
Endo Pharmaceuticals

Unknown

A Pilot Study of Ultra Rapid Opioid Rotation and Titration of Oxymorphone

Neuropathic Pain | Non-cancer Pain | Chronic Nociceptive Pain

United States
Endo Pharmaceuticals

Completed

Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy

Lower Back Pain | Cancers, Pain

United States
Endo Pharmaceuticals

Completed

Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain

Chronic Pain

United States
Endo Pharmaceuticals

Completed

Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain

Chronic Pain

United States
MedVadis Research Corporation

Completed

Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive Functioning

Chronic Pain

United States
Endo Pharmaceuticals

Completed

Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects

Post Operative Pain

United States
Endo Pharmaceuticals

Completed

Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.

Postoperative Pain

United States
Endo Pharmaceuticals

Completed

Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain

Acute Pain

United States
Endo Pharmaceuticals

Terminated

Clinical Study to Evaluate the Effectiveness, Safety, and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects

Acute Pain | Post-Operative Pain

United States
Endo Pharmaceuticals

Completed

Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain

Cancer | Chronic Pain | Neuropathic Pain
Endo Pharmaceuticals

Terminated

Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects

Chronic Pain

United States
New York State Psychiatric Institute
University of Kentucky

Completed

A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists.

Opioid Use Disorder

United States
Endo Pharmaceuticals
Kendle Early Stage - Toronto

Completed

Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)

Healthy

Canada
City of Hope Medical Center
National Cancer Institute (NCI)

Suspended

Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
Roxane Laboratories

Completed

Bioequivalency Study of Oxymorphone Hydrochloride 10 mg Tablets Under Fasted Conditions

Pain

United States
Neelesh Sharma MD PhD

Completed

Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Xijing Hospital of Digestive Diseases

Completed

A Research of Berberine Hydrochloride to Prevent Colorectal Adenomas in Patients With Previous Colorectal Cancer

Colorectal Adenomas

China
Xijing Hospital of Digestive Diseases

Completed

Primary Chemoprevention of Familial Adenomatous Polyposis With Berberine Hydrochloride

Colorectal Adenomas

China
Shenyang Sunshine Pharmaceutical Co., LTD.

Unknown

A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet

Uremic Pruritus

China
Galderma R&D

Completed

Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma

Basal Cell Carcinoma

Australia
M.D. Anderson Cancer Center

Withdrawn

Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8
Betta Pharmaceuticals Co., Ltd.
Tigermed Consulting Co., Ltd

Completed

Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis

Psoriasis

China
Epygenix

Completed

Study of Safety and Pharmacokinetics of Oral Doses of EPX-100 in Healthy Subjects.

Dravet Syndrome

United States
Janssen Research & Development, LLC

Completed

An Observational Study of Men With Premature Ejaculation Who Are Treated With Dapoxetine Hydrochloride or Alternate Care Defined as Any Treatment Other Than Dapoxetine Hydrochloride

Sexual Dysfunction, Physiological | Ejaculation

Germany, Spain, Portugal, Finland, Sweden, Austria
Advanz Pharma

Completed

A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)

Atrial Fibrillation
National Cancer Institute (NCI)

Active, not recruiting

Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal Large B-Cell Lymphoma | Refractory Primary Mediastinal Large B-Cell Lymphoma

United States
Peking University Third Hospital

Not yet recruiting

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer
University of Rochester
Endo Pharmaceuticals

Terminated

Lumbar Stenosis Outcomes Research II (LUSTORII)

Lumbar Spinal Stenosis

United States
WPD Pharmaceuticals Sp. z o.o.
Worldwide Clinical Trials

Not yet recruiting

A Multicenter, Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin in Pediatric Patients With Progressive, Refractory, or Recurrent High Grade Gliomas

High Grade Glioma
PhytoHealth Corporation

Completed

Bioavailability, Pharmacokinetics and Safety Evaluation of Phencynonate Hydrochloride in Healthy Volunteers

Healthy

Taiwan
Zhejiang University
Huashan Hospital; West China Hospital; The First Affiliated Hospital of Zhengzhou... and other collaborators

Terminated

A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence

Hepatocellular Carcinoma

China
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States
National Institute of Allergy and Infectious Diseases...
International Tuberculosis Research Center

Withdrawn

Pimonidazole Hydrochloride to Detect Low Oxygen in Tuberculosis-Infected Lungs

Refractory Pulmonary Tuberculosis

Korea, Republic of
Mundipharma K.K.

Completed

Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies

Recurrent or Refractory T/NK-cell Malignancies

Japan
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

GW786034 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
BioCryst Pharmaceuticals

Completed

Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma

Lymphoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

TLK286 in Treating Patients With Advanced Non-Small Cell Lung Cancer

Lung Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma

Anlotinib | Sarcoma,Soft Tissue | Trunk | Extremity | Intensity-modulated Radiotherapy | Major Wound Complications

China
WPD Pharmaceuticals Sp. z o.o.
National Center for Research and Development, Poland; Worldwide Clinical Trials

Recruiting

Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)

Recurrent Glioblastoma Multiforme

Poland
The First Hospital of Jilin University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLC

Non-Small Cell Lung Cancer

China

Search clinical trials for: oxymorphone hydrochloride

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations